INOVATION IN THE ANTICOAGULANT THERAPY
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v5i3.45 |
Resumo: | Introdution: Atherothrombosis and venous thromboembolism are the leading causes of morbidity and mortality. Anticoagulant therapy is crucial to decrease these factors by preventing the clotting of blood.Objective: Describe some of the new anticoagulant drugs, introduced in an attempt to overcome the limitations of traditional anticoagulant drugs (heparins, warfarin and acenocumarol).Method: Narrative literature review of relevant scientific articles published between 2006 and 2012.Results: A new strategy for the design of new antithrombotic drugs is based on selective inhibition of a specific coagulation factor, with potential to be more effective, safe and easy to use. These include direct thrombin inhibitors (dabigatran, bivalirudin, desirudin, lepirudin and argatroban) and factor Xa inhibitors (otamixaban, rivaroxaban, o apixaban, edoxaban and fondaparinux). Also, a new vitamin K antagonist has been developed, tecarfarin. This does not present the same limitations as the other, which is due essencially to the fact that is not metabolized by CYP450 enzymes.Conclusion: Anticoagulant therapy has been the target of an intense review so that its use in the clinical practice becomes indeed innovative and revolutionary. Currently, in Portugal, only fondaparinux, the dabigatran etexilate and rivaroxaban have been approved and commercialized. |
id |
RCAP_fc26018733abd0ca449748922c01c1ab |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/45 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
INOVATION IN THE ANTICOAGULANT THERAPYINOVAÇÃO NA TERAPÊUTICA ANTICOAGULANTEIntrodution: Atherothrombosis and venous thromboembolism are the leading causes of morbidity and mortality. Anticoagulant therapy is crucial to decrease these factors by preventing the clotting of blood.Objective: Describe some of the new anticoagulant drugs, introduced in an attempt to overcome the limitations of traditional anticoagulant drugs (heparins, warfarin and acenocumarol).Method: Narrative literature review of relevant scientific articles published between 2006 and 2012.Results: A new strategy for the design of new antithrombotic drugs is based on selective inhibition of a specific coagulation factor, with potential to be more effective, safe and easy to use. These include direct thrombin inhibitors (dabigatran, bivalirudin, desirudin, lepirudin and argatroban) and factor Xa inhibitors (otamixaban, rivaroxaban, o apixaban, edoxaban and fondaparinux). Also, a new vitamin K antagonist has been developed, tecarfarin. This does not present the same limitations as the other, which is due essencially to the fact that is not metabolized by CYP450 enzymes.Conclusion: Anticoagulant therapy has been the target of an intense review so that its use in the clinical practice becomes indeed innovative and revolutionary. Currently, in Portugal, only fondaparinux, the dabigatran etexilate and rivaroxaban have been approved and commercialized.Introdução: A trombose arterial e a trombose venosa são ainda a principal causa de morbilidade e mortalidade.A terapêutica anticoagulante é fundamental para diminuir esta morbimortalidade, permitindo a não ocorrência ou o aumento de trombos.Objetivo: Descrever alguns dos novos fármacos anticoagulantes que surgem na tentativa de colmatar as limitações da atual terapêutica (heparinas, varfarina e acenocumarol).Métodos: Revisão narrativa de artigos científicos relevantes publicados entre os anos de 2006 e 2012.Resultados: A estratégia destes novos fármacos antitrombóticos baseia-se na inibição seletiva de um fatorde coagulação específico, obtendo assim inibidores seletivos com potencial para serem mais eficazes, seguros e fáceis de usar. Esta nova classe tem como principais alvos a trombina (bivalirudina, desirudina, lepirudina, argatrobana e dabigatrano) e o FXa (fondaparinux, rivaroxabano, o apixabano, edoxabano), verificando-se, no entanto, também o desenvolvimento de um novo antagonista da vitamina K, a tecarfarina, sem as limitações dos que estão atualmente comercializados, o que se deve essencialmente ao metabolismo não ocorrer via citocromo P450.Conclusões: A terapêutica anticoagulante está a ser alvo de uma intensa investigação, de modo a que a sua utilização na prática clínica seja de facto inovadora e revolucionária. Atualmente, em Portugal, ainda só estão aprovados e comercializáveis o fondaparinux sódico, o dabigatrano etexilato e o rivaroxabano.Formifarma2013-09-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v5i3.45https://doi.org/10.25756/rpf.v5i3.45Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 5 No 3 (2013): Julho; 30-43Revista Portuguesa de Farmacoterapia; v. 5 n. 3 (2013): Julho; 30-432183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/45http://revista.farmacoterapia.pt/index.php/rpf/article/view/45/34Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessRamos, SofiaOliveira Martins, Sofia2023-09-01T04:33:04Zoai:ojs.farmacoterapia.pt:article/45Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:31.298285Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
INOVATION IN THE ANTICOAGULANT THERAPY INOVAÇÃO NA TERAPÊUTICA ANTICOAGULANTE |
title |
INOVATION IN THE ANTICOAGULANT THERAPY |
spellingShingle |
INOVATION IN THE ANTICOAGULANT THERAPY Ramos, Sofia |
title_short |
INOVATION IN THE ANTICOAGULANT THERAPY |
title_full |
INOVATION IN THE ANTICOAGULANT THERAPY |
title_fullStr |
INOVATION IN THE ANTICOAGULANT THERAPY |
title_full_unstemmed |
INOVATION IN THE ANTICOAGULANT THERAPY |
title_sort |
INOVATION IN THE ANTICOAGULANT THERAPY |
author |
Ramos, Sofia |
author_facet |
Ramos, Sofia Oliveira Martins, Sofia |
author_role |
author |
author2 |
Oliveira Martins, Sofia |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Ramos, Sofia Oliveira Martins, Sofia |
description |
Introdution: Atherothrombosis and venous thromboembolism are the leading causes of morbidity and mortality. Anticoagulant therapy is crucial to decrease these factors by preventing the clotting of blood.Objective: Describe some of the new anticoagulant drugs, introduced in an attempt to overcome the limitations of traditional anticoagulant drugs (heparins, warfarin and acenocumarol).Method: Narrative literature review of relevant scientific articles published between 2006 and 2012.Results: A new strategy for the design of new antithrombotic drugs is based on selective inhibition of a specific coagulation factor, with potential to be more effective, safe and easy to use. These include direct thrombin inhibitors (dabigatran, bivalirudin, desirudin, lepirudin and argatroban) and factor Xa inhibitors (otamixaban, rivaroxaban, o apixaban, edoxaban and fondaparinux). Also, a new vitamin K antagonist has been developed, tecarfarin. This does not present the same limitations as the other, which is due essencially to the fact that is not metabolized by CYP450 enzymes.Conclusion: Anticoagulant therapy has been the target of an intense review so that its use in the clinical practice becomes indeed innovative and revolutionary. Currently, in Portugal, only fondaparinux, the dabigatran etexilate and rivaroxaban have been approved and commercialized. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-09-23 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v5i3.45 https://doi.org/10.25756/rpf.v5i3.45 |
url |
https://doi.org/10.25756/rpf.v5i3.45 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/45 http://revista.farmacoterapia.pt/index.php/rpf/article/view/45/34 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 5 No 3 (2013): Julho; 30-43 Revista Portuguesa de Farmacoterapia; v. 5 n. 3 (2013): Julho; 30-43 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129985473052672 |